|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Aliskiren#Use in Specific Populations]] |
| {{Aliskiren}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ===8.1 Pregnancy===
| |
| | |
| ===Pregnancy Category D===
| |
| | |
| Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting [[oligohydramnios]]can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, [[anuria]], [[hypotension]], [[renal failure]], and death. When pregnancy is detected, discontinue Tekturna as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal [[hypertension]] during pregnancy is important to optimize outcomes for both mother and fetus.
| |
| | |
| In the unusual case that there is no appropriate alternative to therapy with drugs affecting the [[renin-angiotensin system]] for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If [[oligohydramnios]]is observed, discontinue Tekturna, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that [[oligohydramnios]]may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Tekturna for [[hypotension]], [[oliguria]], and [[hyperkalemia]]. [see Use in Specific Populations (8.4)]
| |
| | |
| ===8.3 Nursing Mothers===
| |
| | |
| It is not known whether aliskiren is excreted in human breast milk. Aliskiren was secreted in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
| |
| | |
| ===8.4 Pediatric Use===
| |
| | |
| Safety and effectiveness of aliskiren in pediatric patients <18 years have not been established.
| |
| | |
| Neonates with a history of in utero exposure to Tekturna:
| |
| If oliguria or [[hypotension]] occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing [[hypotension]] and/or substituting for disordered renal function.
| |
| | |
| ===8.5 Geriatric Use===
| |
| | |
| Of the total number of patients receiving aliskiren in clinical studies, 1,275 (19%) were 65 years or older and 231 (3.4%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
| |
| | |
| ===8.6 Renal Impairment===
| |
| | |
| Safety and effectiveness of Tekturna in patients with severe renal impairment (CrCL <30 ml/min) have not been established as patients with eGFR <30ml/min were excluded in clinical trials [see Clinical Studies (14)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TEKTURNA (ALISKIREN HEMIFUMARATE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=833c7a0b-5f64-4363-94d5-9a179049113a | publisher = | date = | accessdate = 25 February 2014 }}</ref>
| |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Agents acting on the renin-angiotensin system}}
| |
| | |
| [[Category:Renin inhibitors]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |